Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis
- 278 Downloads
We sought to clarify the prognostic value of CD44 in survival of patients with non-small cell lung cancer (NSCLC). We performed a meta-analysis of relevant literature to aggregate the available survival results, using studies published in English until March 2014. Eligible studies dealt with CD44, CD44 standard form (CD44s) and CD44 variant 6 (CD44v6), assessment in NSCLC patients on primary lesions and reported survival data according to CD44 and CD44 isoforms expression. We aggregated 10 trials (5 trials for CD44v6, 3 trials for CD44, and 2 trials for CD44s) comprising 1,074 patients, in this meta-analysis. The combined hazard ratio (HR) with CD44v6 and CD44s was 2.39 (95 % confidence interval (CI) 1.69–3.37) and 1.64 (95 % CI 1.06–2.52), respectively. It associated high CD44v6 and CD44s expression with poor survival in NSCLC patients. However, CD44 overexpression did not significantly correlate with survival in patients with NSCLC (HR 1.44; 95 % CI 0.72–2.89). Our meta-analysis shows that CD44v6 and CD44s overexpression indicates poor prognosis for NSCLC patients. However, the high CD44 expression is not significantly correlated with survival for patients with NSCLC.
KeywordsCD44 CD44v6 Non-small cell lung cancer Prognosis Meta-analysis Hazard ratio
Wei Zhao and Wei Shao extracted data from eligible studies independently, discussed discrepancies, and reached at least 95 % agreement on all criteria used. Any remaining disagreements were resolved through discussion with the primary investigators or arbitration by a third reviewer (Hao Jiang).
Conflicts of interest
The authors declare that they have no conflict of interest. We declare that we have no financial, professional, or personal relationships with people, organizations, services, or products that inappropriately influence our work or that could be construed as influencing positions presented in this article.